|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 204.00 INR | -2.24% |
|
+1.55% | -17.61% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Contract Research Organization | ||||||||||
Medical Labs & Research | - | - | 2.41TCr | 2.62TCr | 2.71TCr | |||||
Total Assets | - | - | 9.45TCr | 9.58TCr | 10TCr | |||||
Interest Expense | - | - | -74Cr | -113.41Cr | -151.5Cr | |||||
Income Tax Expense | - | - | -25Cr | 31Cr | 16Cr | |||||
CAPEX | - | - | -574.06Cr | -303.25Cr | -216.76Cr | |||||
EBT | - | - | -55Cr | -122.26Cr | 19Cr | |||||
D&A | - | - | 224.17Cr | 258.55Cr | 277.43Cr | |||||
Net Income | - | - | -30Cr | -153.45Cr | 3.24Cr | |||||
Contract Research and Manufacturing Services (CRAMS) | 1.43TCr | 1.65TCr | - | - | - | |||||
Operating Income | -99Cr | -27Cr | - | - | - | |||||
Operating Income | -5.6Cr | -8.8Cr | - | - | - | |||||
Vitamins and Nutritional Supplements | ||||||||||
Vitamin-D, Bulk Drugs, Quats, Speciality Chemicals and Traded Goods | 479.62Cr | 491.35Cr | - | - | - | |||||
Operating Income | 65Cr | 69Cr | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of The World | 1.87TCr | 2.1TCr | - | - | - | |||||
Total Assets | 5.71TCr | 6.41TCr | - | - | - | |||||
India | 44Cr | 37Cr | - | - | - | |||||
Total Assets | 2.62TCr | 2.23TCr | - | - | - |
- Stock Market
- Equities
- DCAL Stock
- Financials Dishman Carbogen Amcis Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition